미국의 화상 치료 : 시장 점유율 분석, 산업 동향 및 통계 데이터, 성장 예측(2026-2031년)

According to Mordor Intelligence, the united states burn care market size was valued at USD 1.38 billion in 2025 and is estimated to grow from USD 1.46 billion in 2026 to reach USD 1.96 billion by 2031, at a CAGR of 5.95% during the forecast period (2026-2031).

This report is Segmented by Product Type (Advanced Dressings [Foam Dressings, and More], Biologics and Skin Substitutes, and More), Burn Depth (Superficial, Partial-Thickness, Full-Thickness Burns), Care Setting (Hospitals, Specialised Burn Centres and Wound Clinics, and More), and Burn Etiology (Thermal, Electrical, and More). The Market Forecasts are Provided in Terms of Value (USD).

United States Burn Care Market Trends and Insights

High U.S. Burn Case Burden and Concentrated Referral Flows

The United States burn care market continues to benefit from a large and steady treatment base because the CDC-linked burn burden stands near 398,000 fire or burn-related injuries annually, while the American Burn Association reported that 29,165 cases required inpatient admission. Demand is not spread evenly across the country because 94 hospitals that each admit at least 100 burn encounters per year account for 81% of all inpatient burn admissions. This concentration creates dependable purchasing nodes where formulary access matters more than broad but shallow distribution coverage. The South Atlantic alone contributes 26% of inpatient burn admissions, which gives that region a larger role in infrastructure planning and supplier prioritization. In the United States burn care market, product adoption is therefore tied closely to referral velocity through ABA-verified centers and high-volume hospitals. Manufacturers with direct access to these high-throughput institutions are better placed to secure repeat use across advanced dressings, grafts, and support therapies.

Advanced Dressings, Grafts, and Biologics Adoption

The United States burn care market is shifting toward care pathways that combine advanced dressings with biologics rather than treating the two categories as separate choices. Burn surgeons are using staged treatment protocols more often for full-thickness and deep partial-thickness injuries, which raises demand for dermal templates, graft-support products, and adjunct wound coverage. Integra LifeSciences presented real-world evidence from 985 cases and a 23-patient burn series across three conferences in April 2026, which shows that dermal regeneration templates are moving into routine institutional algorithms. At the same time, dressing volumes remain firm because formulary teams still favor a dressing-first approach for many partial-thickness wounds before escalating to higher-cost biologic products. Regulatory activity is reinforcing this trend because the FDA cleared AVITA Medical's Cohealyx collagen-based dermal matrix and PermeaDerm biosynthetic wound matrix, while the FDA approved Abeona Therapeutics' ZEVASKYN in April 2025, which signals that high-evidence products can still move forward. This combination of broader clinical acceptance and a higher evidence threshold keeps both advanced dressings and biologics in positive growth territory within the United States burn care market.

High Cost of Biologics and NPWT-Intensive Care Pathways

The United States burn care market faces a clear adoption ceiling when treatment pathways depend heavily on biologics and NPWT. The American Burn Association reported that 29.1% of burn patients were covered by Medicaid and 10.2% were uninsured or self-paying, which limits the ability of many facilities to absorb expensive advanced therapies. NPWT-assisted graft preparation can add USD 1,000-3,000 per dressing change episode in inpatient care, which makes cost justification difficult in community hospitals without strong outcomes data. The payer mix becomes even more restrictive because 15.9% of burn-center patients are on Medicare and facilities now face tighter reimbursement for many skin substitutes. In response, manufacturers are leaning more heavily on real-world evidence such as Integra's PriMatrix publications and Kerecis data on reduced hospital length of stay to support economic value discussions. These cost pressures slow the pace at which newer products can scale across the full United States burn care market.

Other drivers and restraints analyzed in the detailed report include:

1. Burn-Centre Expansion and Outpatient Pathway Optimization
2. Teleburn Networks Closing Rural Access Gaps
3. CMS 2026 Skin-Substitute Payment Reset

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Advanced dressings held the leading position in the United States burn care market, accounting for 42.31% of revenue in 2025. Their lead reflects broad use across superficial, partial-thickness, and selected post-surgical wounds in hospitals, ambulatory settings, and home recovery programs. Antimicrobial silver dressings and foam dressings remain the most widely used formats because they address infection control and exudate management across a large patient pool. Smith+Nephew's March 2026 launch of ALLEVYN COMPLETE CARE, which cited stronger exudate management performance than competing products, shows that innovation continues to support premium pricing in this tier.

Biologics and skin substitutes are the fastest-growing product segment in the United States burn care market, with an 8.38% CAGR expected from 2026 to 2031. This growth reflects stronger clinical use in full-thickness and complex deep partial-thickness injuries, along with a regulatory shift that now favors BLA-pathway products. Vericel reported that NexoBrid generated USD 12.0 million in burn care revenue in Q1 2026, up 91% year on year, and the company raised its full-year 2026 guidance to USD 44-48 million. Negative pressure wound therapy remains an important support layer in graft preparation and wound management, while traditional dressings still hold a cost-led role in facilities that cannot absorb higher biologic spending. The United States burn care market therefore shows a two-track product structure where advanced dressings preserve scale and biologics capture the fastest revenue growth.

Partial-thickness burns represented 63.24% in 2025, giving them the largest role in the United States burn care market by burn depth. This share follows the clinical pattern reported by the American Burn Association, where deep partial-thickness injuries requiring surgery but not prolonged ventilation made up 32% of hospital admissions, while the most extensive injuries requiring both surgery and ventilation accounted for only 4.4%. Foam, hydrocolloid, alginate, and other advanced dressings remain the backbone for these wounds because they support healing while limiting unnecessary escalation. Enzymatic debridement products such as NexoBrid are also gaining traction in deep partial-thickness care because they can remove eschar selectively without sacrificing viable tissue, a treatment approach reflected in recent clinical guidance.

Full-thickness burns are forecast to expand at a 7.52% CAGR from 2026 to 2031, making them the fastest-growing burn-depth category in the United States burn care market. Their growth matters because these injuries carry higher product complexity, heavier surgical use, and greater revenue per episode than superficial burns. PolyNovo's NovoSorb BTM remains in a multicenter pivotal study at U.S. burn centers including Valleywise Health and LAC+USC, with estimated completion in December 2026, which could support wider use of synthetic matrices in excision-and-graft protocols. Superficial burns still contribute large case volume, but their lower treatment intensity limits their value contribution. This pattern keeps the United States burn care market anchored by partial-thickness prevalence while allowing full-thickness cases to drive product sophistication and premiumization.

List of Companies Covered in this Report:

1. AROA Biosurgery
2. Avita Medical
3. Coloplast
4. Convatec
5. DeRoyal Industries
6. Human BioSciences
7. Integra LifeSciences
8. Kerecis
9. Mallinckrodt Pharmaceuticals
10. MediWound
11. Medline Industries
12. MIMEDX Group
13. Molnlycke Health Care
14. MTF Biologics
15. Organogenesis
16. PolyNovo
17. Smiths Group
18. Solventum
19. Vericel

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 High U.S. Burn Case Burden and Concentrated Referral Flows
  • 4.2.2 Advanced Dressings, Grafts, and Biologics Adoption
  • 4.2.3 Burn-Center Expansion and Outpatient Pathway Optimization
  • 4.2.4 Teleburn Networks Closing Rural Access Gaps
  • 4.2.5 Lithium-Ion Battery Fires Increasing High-Acuity Cases
  • 4.2.6 BARDA-Backed Severe-Burn Preparedness and Domestic Capacity
• 4.3 Market Restraints
  • 4.3.1 High Cost of Biologics and NPWT-Intensive Care Pathways
  • 4.3.2 CMS 2026 Skin-Substitute Payment Reset
  • 4.3.3 Rural Burn-Center Access and Specialist Staffing Gaps
  • 4.3.4 Higher Evidence and Regulatory Bar for Advanced Biologics
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Product Type
  • 5.1.1 Advanced Dressings
    • 5.1.1.1 Foam Dressings
    • 5.1.1.2 Hydrocolloid Dressings
    • 5.1.1.3 Hydrogel Dressings
    • 5.1.1.4 Alginate Dressings
    • 5.1.1.5 Antimicrobial Silver Dressings
    • 5.1.1.6 Collagen Dressings
    • 5.1.1.7 Silicone Contact Layers
  • 5.1.2 Biologics and Skin Substitutes
  • 5.1.3 Negative Pressure Wound Therapy
  • 5.1.4 Traditional Dressings
  • 5.1.5 Other Product Types
• 5.2 By Burn Depth
  • 5.2.1 Superficial Burns
  • 5.2.2 Partial-Thickness Burns
  • 5.2.3 Full-Thickness Burns
• 5.3 By Care Setting
  • 5.3.1 Hospitals
  • 5.3.2 Specialised Burn Centres and Wound Clinics
  • 5.3.3 Ambulatory Surgery Centers
  • 5.3.4 Home Health and Virtual Follow-up
  • 5.3.5 Other Care Settings
• 5.4 By Burn Etiology
  • 5.4.1 Thermal Burns
  • 5.4.2 Electrical Burns
  • 5.4.3 Chemical Burns
  • 5.4.4 Radiation and Friction Burns

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 AROA Biosurgery
  • 6.3.2 AVITA Medical
  • 6.3.3 Coloplast
  • 6.3.4 ConvaTec Group
  • 6.3.5 DeRoyal Industries
  • 6.3.6 Human BioSciences
  • 6.3.7 Integra LifeSciences
  • 6.3.8 Kerecis
  • 6.3.9 Mallinckrodt
  • 6.3.10 MediWound
  • 6.3.11 Medline Industries
  • 6.3.12 MIMEDX Group
  • 6.3.13 Molnlycke Health Care
  • 6.3.14 MTF Biologics
  • 6.3.15 Organogenesis
  • 6.3.16 PolyNovo
  • 6.3.17 Smith+Nephew
  • 6.3.18 Solventum
  • 6.3.19 Vericel Corporation

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment